[1]
Lee, J.C., Hung, J.-Y., Kim, Y.-C., Chang, G.-C., Yoo, S., Yang, S.-H., Davis, K., Nagar, S., Taylor, A., Lee, S. and Shih, J.-Y. 2021. Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan. Asian Pacific Journal of Cancer Biology. 6, 2 (May 2021), 123-132. DOI:https://doi.org/10.31557/apjcb.2021.6.2.123-132.